Preclinical Imaging Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Photoacoustic Imaging Systems is the fastest growing sector, North America is the largest market

The Global Preclinical Imaging Market is projected to expand significantly, rising from USD 5.77 Billion in 2025 to USD 8.31 Billion by 2031, demonstrating a compound annual growth rate of 6.27%. This market involves visualizing and quantifying physiological and pathological processes in small animal models using technologies such as MRI, CT, and PET to advance drug development and disease research. Its primary growth is fueled by the escalating demand for non-invasive longitudinal studies, which align with ethical guidelines to reduce animal cohort sizes while simultaneously enhancing the precision of translational data.

Moreover, substantial capital allocation towards pharmaceutical discovery, particularly in areas like oncology and neurology, serves as a key impetus for the adoption of these in vivo observation technologies.Despite its positive growth trajectory, the market faces a considerable hurdle due to the high acquisition and operational expenses associated with advanced high-resolution multi-modal instrumentation, which often restricts access for smaller research facilities. Nevertheless, the broader financial landscape for the life sciences sector remains robust, providing a stable foundation for the procurement of such technologies. For instance, in 2025, the pharmaceutical industry invested an estimated €55 billion in research and development across Europe, according to the European Federation of Pharmaceutical Industries and Associations, highlighting the sustained financial support for demand-driving validation tools.

Market Drivers

Increased research and development expenditure within the pharmaceutical sector acts as a principal driver for the expansion of the preclinical imaging market. As the process of drug discovery grows more intricate, leading pharmaceutical companies are dedicating substantial financial resources to early-stage validation, aiming to confirm molecule viability before progression to human clinical trials. This significant increase in spending directly stimulates the acquisition of high-fidelity imaging instrumentation, which is essential for rigorous safety and efficacy assessments.

For example, Johnson & Johnson escalated its research and development investment to approximately $17.1 billion in 2024, as reported by Fierce Biotech in March 2025, underscoring the aggressive investment strategies prevalent across the industry, which ensures consistent demand for critical validation tools designed to lower attrition rates in drug development.The escalating prevalence of chronic diseases further strengthens the market's upward trajectory by necessitating more extensive animal model studies for translational research.

The urgent requirement to comprehend pathological mechanisms in fields such as oncology, neurology, and cardiology compels research institutions to employ non-invasive imaging for continuous monitoring of disease progression and treatment responses. The American Cancer Society projected over 2 million new cancer cases in the United States in 2025, as noted in its January 2025 report, highlighting the critical disease burden that accelerates therapeutic discovery efforts. To support this intensive research ecosystem, major instrument providers maintain considerable operational scales; for instance, Bruker Corporation reported quarterly revenues of $860.5 million in its November 2025 financial results, signifying the substantial commercial activity underpinning life sciences instrumentation.

Market Challenges

The prohibitive acquisition and ongoing operational costs linked with high-resolution multi-modal instrumentation present a significant impediment to the growth of the global preclinical imaging market. These sophisticated imaging systems demand substantial initial capital investment along with considerable recurrent budgets for maintenance and specialized staff. This situation disproportionately impacts smaller research organizations and academic institutions that typically possess limited financial flexibility.

During periods of reduced funding cycles or tighter grant availability, these entities often find their capacity to acquire essential imaging technology immediately constrained, leading to delayed purchases and continued reliance on older, less efficient modalities.This financial burden is further intensified by recent reductions in public funding, which traditionally serves as a vital revenue source for equipment procurement. For instance, the Association of American Universities noted a sharp decline in federal research awards in 2025, with National Institutes of Health awards decreasing by 29 percent compared to historical averages. Such a substantial decrease in available capital directly hinders the market's growth potential by confining the accessible customer base primarily to well-capitalized pharmaceutical entities, thereby restricting broader adoption rates throughout the scientific community.

Market Trends

The integration of Artificial Intelligence and Machine Learning for automated image analysis is fundamentally transforming preclinical workflows, shifting the focus from qualitative observation to quantitative, high-throughput phenotyping. Unlike conventional manual interpretation, which is susceptible to variability, AI algorithms now facilitate the unbiased extraction of morphological features across vast datasets, effectively elevating imaging to a primary screening modality in drug discovery.

This move towards industrialized biology is well-illustrated by companies such as Recursion Pharmaceuticals, which utilizes AI-enabled phenomics to decipher biological maps and accelerate therapeutic validation; the company reported full-year revenue of $58.8 million in its February 2025 financial results, reflecting the increasing commercial acceptance of computational drug discovery platforms heavily dependent on automated, large-scale imaging datasets.The convergence of hybrid and multimodal imaging platforms represents a crucial technological advancement, enabling researchers to correlate functional molecular signals with precise anatomical structures within a single experimental session.

This trend addresses the limitations of individual modalities by integrating complementary technologies, such as optical imaging with micro-CT or PET with MRI, to offer comprehensive physiological insights while simultaneously minimizing animal handling and anesthesia-induced stress. Leading instrument manufacturers are actively expanding these hybrid portfolios to satisfy the complex data requirements of translational medicine. For example, Revvity reported annual revenue of approximately $2.76 billion in its January 2025 financial results, a figure supported by its strategic emphasis on specialized diagnostics and life sciences solutions, including advanced multimodal systems like the IVIS SpectrumCT series.

Key Market Players

• Aspect Imaging Ltd
• Bruker Corporation
• Fujifilm Holdings Corporation
• Mediso Ltd
• MR Solutions Ltd
• PerkinElmer Inc.
• United Imaging Healthcare Co. Ltd
• AXT PTY LTD
• Advanced Molecular Vision, Inc.
• IVIM Technology Corp

Report Scope

In this report, the Global Preclinical Imaging Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preclinical Imaging Market, by Modality:

• Optical Imaging Systems
• Nuclear Imaging Systems
• Micro-MRI
• Micro-ultrasound
• Micro-CT
• Photoacoustic Imaging Systems
• Other

Preclinical Imaging Market, by Application:

• Research and Development
• Drug Discovery

Preclinical Imaging Market, by End User:

• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutes
• Others

Preclinical Imaging Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preclinical Imaging Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.